Advertisement

Topics

Chimeric Therapies Incorporated Company Profile

10:57 EST 18th November 2017 | BioPortfolio

Chimeric Therapirs Incorporated is committed to developing bone marrow graft engineering to expand the use of safe and effective cellular grafts tailored to treat and cure diseases.

Location

28202 Cabot Road, Suite 210
Laguna Niguel
CA
92677
United States of America

Contact

Phone: 281 851 3035
Fax: 281 361 8463


News Articles [246 Associated News Articles listed on BioPortfolio]

Unleashing CAR-T Therapies on Solid Tumors: Are We There Yet?

Chimeric antigen receptor (CAR) T cell therapies have shown dramatic results against certain blood cancers ...

Following IBMTR model may make CAR-T therapies affordable, says oncologist and data specialist

News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy…

Chimeric antigen receptor T-cell therapies for lymphoma

Cell-based immunotherapies are showing great promise in the treatment of even the most treatment-refractory of haematological malignancies. Herein, Jennifer Brudno and James Kochenderfer review the re...

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Chimeric antigen receptor (CAR)-T-cell therapies are showing great promise in the treatment of cancer, particularly B-cell malignancies, but are associated with characteristic, potentially fatal toxic...

Comprehensive in silico allergenicity assessment of novel protein engineered chimeric Cry proteins for safe deployment in crops

Development of chimeric Cry toxins by protein engineering of known and validated proteins is imperative for enhancing the efficacy and broadening the insecticidal spectrum of these genes. Expression o...

FDA Approval of Tisagenlecleucel as CAR-T Therapy for Leukemia

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the ...

‘Incredibly Exciting’: CAR T Cells as ‘Living Drugs’

(Medscape) – “Incredibly exciting” is how experts are describing the new development with chimeric antigen receptor (CAR) T cells, as the first of these novel therapies approaches th...

Servier, Transgene Leverage Platform Tech for More Effective CAR T-Cell Therapies

Servier and Transgene have established a research collaboration to evaluate the latter’s viral vectorization technologies for use in engineering allogeneic chimeric antigen receptor (CAR) T-cell the...

PubMed Articles [699 Associated PubMed Articles listed on BioPortfolio]

Understanding clinical development of chimeric antigen receptor T cell therapies.

In the past decade, many clinical trials with gene- and cell-based therapies (GCTs) have been performed. Increased interest in the development of these drug products by various stakeholders has become...

Chimeric RNAs and their implications in cancer.

Chimeric RNAs have been believed to be solely produced by gene fusions resulting from chromosomal rearrangement, thus unique features of cancer. Detected chimeric RNAs have also been viewed as surroga...

Hopes and Difficulties for Blastocyst Complementation.

The clinical need for organ replacement therapies has inspired the idea of growing human organs in animal hosts. The injection of human pluripotent stem cells into animal blastocysts provides a possib...

Emerging Principles from the Clinical Application of Chimeric Antigen Receptor (CAR) T Cell Therapies for B Cell Malignancies.

Gene-engineered T cell therapies are soon to be FDA approved for at least two types of B cell malignancies in pediatric and adult patients, in the form of CD19 targeted chimeric antigen receptor T (CA...

Neutralized chimeric DNA probe for detection of single nucleotide polymorphism on surface plasmon resonance biosensor.

An implementation of neutralized chimeric DNA oligomer as a probe for sensitive detection of single nucleotide polymorphisms (SNPs) on a surface plasmon resonance imaging sensor is investigated. The c...

Clinical Trials [1522 Associated Clinical Trials listed on BioPortfolio]

Anti-IL-6 Chimeric Monoclonal Antibody in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others...

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positi...

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, react...

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Objectives: The purpose of this study is to evaluate the safety and prognosis of New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T (nCAR19-T) Cells in the treatment of...

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a human...

Companies [830 Associated Companies listed on BioPortfolio]

Chimeric Therapies Incorporated

Chimeric Therapirs Incorporated is committed to developing bone marrow graft engineering to expand the use of safe and effective cellular grafts tailored to treat and cure diseases.

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

CARMA Therapeutics Inc.

CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimer...

Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medica...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

More Information about "Chimeric Therapies Incorporated" on BioPortfolio

We have published hundreds of Chimeric Therapies Incorporated news stories on BioPortfolio along with dozens of Chimeric Therapies Incorporated Clinical Trials and PubMed Articles about Chimeric Therapies Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chimeric Therapies Incorporated Companies in our database. You can also find out about relevant Chimeric Therapies Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Corporate Database Quicklinks



Searches Linking to this Company Record